17.68
0.48 (2.79%)
| Penutupan Terdahulu | 17.20 |
| Buka | 17.40 |
| Jumlah Dagangan | 905,734 |
| Purata Dagangan (3B) | 1,489,170 |
| Modal Pasaran | 1,792,208,000 |
| Harga / Jualan (P/S) | 16.59 |
| Harga / Buku (P/B) | 4.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Jan 2026 |
| Margin Operasi (TTM) | -340.67% |
| EPS Cair (TTM) | -2.60 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.54% |
| Nisbah Semasa (MRQ) | 6.26 |
| Aliran Tunai Operasi (OCF TTM) | -191.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -106.56 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nurix Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.20 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.41% |
| % Dimiliki oleh Institusi | 111.85% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 32.00 (Piper Sandler, 81.00%) | Beli |
| Median | 27.00 (52.72%) | |
| Rendah | 15.00 (Morgan Stanley, -15.16%) | Pegang |
| Purata | 25.67 (45.19%) | |
| Jumlah | 8 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 11.46 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 24 Nov 2025 | 30.00 (69.68%) | Beli | 17.15 |
| BTIG | 04 Nov 2025 | 27.00 (52.71%) | Beli | 12.26 |
| 23 Oct 2025 | 27.00 (52.71%) | Beli | 10.40 | |
| Needham | 04 Nov 2025 | 26.00 (47.06%) | Beli | 12.26 |
| 22 Oct 2025 | 26.00 (47.06%) | Beli | 10.63 | |
| HC Wainwright & Co. | 27 Oct 2025 | 28.00 (58.37%) | Beli | 11.98 |
| 20 Oct 2025 | 33.00 (86.65%) | Beli | 10.39 | |
| Wells Fargo | 23 Oct 2025 | 21.00 (18.78%) | Beli | 10.40 |
| Mizuho | 21 Oct 2025 | 24.00 (35.75%) | Beli | 10.42 |
| Morgan Stanley | 14 Oct 2025 | 15.00 (-15.16%) | Pegang | 9.18 |
| Oppenheimer | 10 Oct 2025 | 28.00 (58.37%) | Beli | 9.76 |
| Piper Sandler | 10 Oct 2025 | 32.00 (81.00%) | Beli | 9.76 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| RING CHRISTINE | - | 17.15 | -37,600 | -644,840 |
| Jumlah Keseluruhan Kuantiti Bersih | -37,600 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -644,840 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 17.15 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | Pegawai | 24 Nov 2025 | Jual automatik (-) | 37,600 | 17.15 | 644,840 |
| RING CHRISTINE | Pegawai | 24 Nov 2025 | Pelaksanaan pilihan | 37,600 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |